Peel Therapeutics: From Elephants, Trees And Honeybees To Cancer Therapeutics
Through Evolutionary Biology
With $36m in seed funding under its belt, Peel Therapeutics is harnessing the power of Darwinian science as it advances a pipeline of cancer and anti-inflammation assets inspired by plant and animal kingdoms.
You may also be interested in...
Real-world cases of retinal vasculitis linked with Syfovre for geographic atrophy in age-related macular degeneration may have resulted from a material used in a specific filter needle, the US firm revealed, as analysts remained optimistic on the product.
Geron’s highly anticipated telomerase inhibitor has been given a user fee date by the US Food and Drug Administration next year and will also be subject to an advisory committee meeting, despite largely positive analyst sentiment on clinical results to date.